Analysts at Canaccord Genuity began coverage on shares of Immunogen (NASDAQ:IMGN) in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Canaccord Genuity’s price target points to a potential upside of 56.25% from the stock’s previous close. ImmunoGen, Inc. (NASDAQ:IMGN) shares after opening at $13.49 moved to $14.79 on last trade day and at the end of the day closed at $14.21. Company price to sales ratio in past twelve months was calculated as 16.00 and price to cash ratio as 6.84. ImmunoGen, Inc. (NASDAQ:IMGN) showed a negative weekly performance of -3.60%.
Horizon Pharma, Inc. (NASDAQ:HZNP) announced that it has received notice of the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with its proposed acquisition of Vidara Therapeutics International Ltd. (“Vidara”). The waiting period was scheduled to expire on May 1, 2014. Horizon Pharma Inc. (NASDAQ:HZNP) shares advanced 7.24% in last trading session and ended the day on $13.18. HZNP return on equity ratio is recorded as -340.20% and its return on assets is -80.60%. Horizon Pharma Inc. (NASDAQ:HZNP) yearly performance is 480.62%.
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Zalicus, Inc. (NASDAQ:ZLCS) relating to the proposed merger with Epirus Biopharmaceuticals, Inc. (“Epirus”). Zalicus Inc. (NASDAQ:ZLCS) shares moved up 31.07% in last trading session and was closed at $1.35, while trading in range of $1.16 – $1.74. Zalicus Inc. (NASDAQ:ZLCS) year to date (YTD) performance is 21.62%.
OXiGENE Inc. (NASDAQ:OXGN) on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 25.2% when compared to the same quarter one year ago, falling from -$1.68 million to -$2.10 million. OXiGENE Inc. (NASDAQ:OXGN) weekly performance is -14.86%. On last trading day company shares ended up $2.98. OXiGENE Inc. (NASDAQ:OXGN) distance from 50-day simple moving average (SMA50) is 2.17%. Analysts mean target price for the company is $1.20.